Literature DB >> 24572677

Surgical debulking for idiopathic dacryoadenitis: a diagnosis and a cure.

Ilse Mombaerts1, J Douglas Cameron2, Waruttaporn Chanlalit3, James A Garrity4.   

Abstract

PURPOSE: Idiopathic inflammatory tumor of the lacrimal gland, also called idiopathic dacryoadenitis, generally is treated with high-dose, long-term systemic corticosteroids, despite their limited success, high recurrence rate, and incidence of drug-induced side effects. This study describes the outcome of patients with idiopathic dacryoadenitis who were managed with surgical debulking.
DESIGN: Retrospective case series from 2 tertiary referral centers. PARTICIPANTS: Forty-six patients (46 lacrimal glands).
METHODS: Review of the clinical records, radiologic scans, and histopathologic specimens, with additional immunoglobulin G4 immunostaining. MAIN OUTCOME MEASURES: Clinical signs and symptoms at 2 months after the surgery and off medications.
RESULTS: Before referral, 41% (19 of 46) of the patients had received systemic high-dose corticosteroids, after which they all showed recurrence, of whom 26% (5 of 19) became dependent on corticosteroids. At referral, all patients underwent debulking surgery of the inflammatory lacrimal gland mass for diagnostic and therapeutic reasons. Additionally, intralesional or systemic low-dose corticosteroids were given during the operation or the first postoperative days in 54% (25 of 46) of the patients. At 2 months after the debulking surgery, a full clinical recovery was seen in 80% (37 of 46) of the patients. A recurrence occurred in 8% (3 of 37) of the patients 4 months and 2.2 and 4.6 years later. Surgical failure (20%; 9 of 46) was correlated with prior corticosteroid treatment (P = 0.002, Fisher exact test), but not with sclerosing inflammation present in 28% (13 of 46). The median follow-up time was 7.2 years (range, 0.7-18 years).
CONCLUSIONS: Debulking biopsy procedures for idiopathic dacryoadenitis, in addition to being diagnostic, may be therapeutic.
Copyright © 2014 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24572677     DOI: 10.1016/j.ophtha.2013.09.010

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  8 in total

1.  Consensus on Diagnostic Criteria of Idiopathic Orbital Inflammation Using a Modified Delphi Approach.

Authors:  Ilse Mombaerts; Jurij R Bilyk; Geoffrey E Rose; Alan A McNab; Aaron Fay; Peter J Dolman; Richard C Allen; Martin H Devoto; Gerald J Harris
Journal:  JAMA Ophthalmol       Date:  2017-07-01       Impact factor: 7.389

2.  Masses of the Lacrimal Gland: Evaluation and Treatment.

Authors:  Jane S Kim; Jason Liss
Journal:  J Neurol Surg B Skull Base       Date:  2021-02-18

3.  Not a Tumor-Nonspecific Orbital Inflammation.

Authors:  James A Garrity
Journal:  J Neurol Surg B Skull Base       Date:  2021-02-02

4.  Lacrimal gland tumors in Turkey: types, frequency, and outcomes.

Authors:  Yağmur Seda Yeşiltaş; Ahmet Kaan Gündüz; Esra Erden; Carol L Shields
Journal:  Int J Ophthalmol       Date:  2018-08-18       Impact factor: 1.779

5.  Corticosteroid Withdrawal after Complete Resection of Recurrent IgG4-Related Ophthalmic Disease.

Authors:  Yuki Hamano; Yoshiyuki Kitaguchi; Kohji Nishida
Journal:  Neuroophthalmology       Date:  2020-03-18

6.  The pathological features of ectopic lymphoid neogenesis in idiopathic dacryoadenitis.

Authors:  Jie Guo; Jiang Qian; Rui Zhang
Journal:  BMC Ophthalmol       Date:  2016-05-26       Impact factor: 2.209

Review 7.  Idiopathic Orbital Inflammation: Review of Literature and New Advances.

Authors:  Yağmur Seda Yeşiltaş; Ahmet Kaan Gündüz
Journal:  Middle East Afr J Ophthalmol       Date:  2018 Apr-Jun

Review 8.  Non-Cancer Effects following Ionizing Irradiation Involving the Eye and Orbit.

Authors:  Juliette Thariat; Arnaud Martel; Alexandre Matet; Olivier Loria; Laurent Kodjikian; Anh-Minh Nguyen; Laurence Rosier; Joël Herault; Sacha Nahon-Estève; Thibaud Mathis
Journal:  Cancers (Basel)       Date:  2022-02-25       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.